Mitigating Progression of Liver Fibrosis in HIV/HCV CoinfectionPremiere Date: Tuesday, May 10, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, May 10, 2023
|Nancy Reau, MD (Moderator)
Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center
|Christian B. Ramers, MD, MPH, FIDSA, AAHIVS
Chief, Population Health
Family Health Centers of San Diego
Associate Clinical Professor
UC San Diego School of Medicine
San Diego, CA
|Joseph K. Lim, MD (Reviewer/Advisor)
Professor of Medicine
Director, Clinical Hepatology
Section of Digestive Diseases/Yale Liver Center
Yale University School of Medicine
New Haven, CT
The management of complex cases such as human immunodeficiency virus (HIV) with hepatitis C virus (HCV) coinfection requires awareness and application of the most current real-world efficacy and safety data as well as guidelines. In HIV/HCV coinfection, it is particularly important to mitigate progression of liver-related morbidity and mortality while maintaining awareness of potential drug-drug interactions that can occur between antiretroviral regimens and direct-acting antivirals (DAAs). The American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) treatment guidelines encompass all types of HCV case scenarios, including uncomplicated (treatment-naïve disease without cirrhosis) and complex (such as HIV/HCV coinfection) cases. It is vital that clinicians refer to the current guidelines and efficacy and safety data in order to make knowledgeable treatment decisions for all patient groups.
This CMEO BriefCase will introduce a complex case involving treatment and management considerations for a patient with HIV and HCV. Join Drs. Nancy Reau and Christian Ramers as they explore the epidemiology and shared pathobiology of liver fibrosis in HIV/HCV, real-world data for available therapies, contraindicated agent combinations, and when and how to treat.
At the end of this CE activity, participants should be able to:
- Apply efficacy and safety data to treatment decisions for optimal management of HCV.
Supported by an educational grant from Gilead Sciences, Inc.
U.S. and international physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in primary care
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Reau reports the following financial relationships:
Consultant: AbbVie Inc.; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; and Merck & Co., Inc.
Grants/Research Support: GENFIT; Intercept Pharmaceuticals, Inc.; and Shire
Dr. Ramers reports the following financial relationships:
Advisory Board: AbbVie Inc. and Gilead Sciences, Inc.
Consultant: AbbVie Inc.; Gilead Sciences, Inc.; and ViiV Healthcare
Grants (Institutional Support): Gilead Sciences, Inc.
Grants (Programmatic Support): AbbVie Inc. and Gilead Sciences, Inc.
Speakers Bureau: AbbVie Inc.; Gilead Sciences, Inc.; and ViiV Healthcare
Dr. Lim (Reviewer/Advisor) reports the following financial relationships:
Research Support: Allergan; Celgene Corporation; Eiger BioPharmaceuticals, Inc.; GENFIT; Gilead Sciences, Inc.; Pfizer Inc.; and Viking Therapeutics
The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).